Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Nasdaq · CIK 0001178670 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

18 Form 4 transaction lines observed in the same window
6 sales · 12 option, withholding, award, gift or other lines

Last qualifying purchase2024-10-17 · Reitan Colleen F · $1.2K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
PYOTT DAVID E IDirector
○○▼
SCHULMAN AMY WDirector
○○
Sigal Charles ElliottDirector
○
Reitan Colleen FDirector
○
KELLOGG PETER NDirector
○
HAMBURG MARGARET ADirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 5 additional owner(s) remain in Form 4 evidence.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-10-17 · Reitan Colleen F.

Recent Form 4 activity

0Purchases
279Sales
42Other Form 4 lines
43SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING6 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-17.1%
3M
-29.2%
6M
-30.5%
12M
—

Volatility & liquidity

Volatility
48.0%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
8.4%
ROE
39.8%
Industry
Biotechnology

Market data

Price data up to: 2026-10-02 · Price source: OpenBB/yfinance · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
7,711,495
Previous report
7,194,097
Avg daily volume
1,195,107
Days to cover
6.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-10-17Reitan Colleen FPurchase (P)Common Stock4USD 302.67USD 1,211SEC filing ↗
2024-08-29Reitan Colleen FPurchase (P)Common Stock32USD 286.00USD 9,152SEC filing ↗

Form 4 evidence

321 transaction lines in the latest 365-day window; 1,327 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02SUPRAN BRYANSale (S)Common Stock1,758USD 226.88USD 398,855SEC filing ↗
2026-09-19Greenstreet YvonneAward / grant (A)Common Stock107USD 0.00USD 0SEC filing ↗
2026-06-01PYOTT DAVID E ISale (S)Common Stock3,830USD 299.18USD 1,145,853SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02SUPRAN BRYANSale (S)Common Stock1,758USD 226.88USD 398,855SEC filing ↗
2026-09-19Greenstreet YvonneAward / grant (A)Common Stock107USD 0.00USD 0SEC filing ↗
2026-06-01PYOTT DAVID E ISale (S)Common Stock3,830USD 299.18USD 1,145,853SEC filing ↗
2026-06-01PYOTT DAVID E IOption exercise / conversion (M)Common Stock3,830USD 0.00USD 0SEC filing ↗
2026-05-20Sigal Charles ElliottAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20SCHULMAN AMY WAward / grant (A)Common Stock838USD 0.00USD 0SEC filing ↗
2026-05-20Reitan Colleen FAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20PYOTT DAVID E IAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20KELLOGG PETER NAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20HAMBURG MARGARET AAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20BRANDICOURT OLIVIERAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20Ausiello Dennis AAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-20Arbuckle Stuart AAward / grant (A)Common Stock671USD 0.00USD 0SEC filing ↗
2026-05-13SCHULMAN AMY WOption exercise / conversion (M)Common Stock11,250USD 70.20USD 789,750SEC filing ↗
2026-04-06McLaughlin MelissaSale (S)Common Stock2,286USD 330.42USD 755,329SEC filing ↗
2026-04-02McLaughlin MelissaSale (S)Common Stock1,624USD 319.59USD 519,014SEC filing ↗
2026-03-05Garg PushkalSale (S)Common Stock2,404USD 323.96USD 778,812SEC filing ↗
2026-03-05Fitzgerald Kevin JosephSale (S)Common Stock658USD 323.98USD 213,177SEC filing ↗
2026-03-04Tanguler TolgaSale (S)Common Stock2,309USD 323.08USD 745,984SEC filing ↗
2026-03-04Poulton Jeffrey V.Sale (S)Common Stock2,468USD 323.08USD 797,351SEC filing ↗
2026-03-04Greenstreet YvonneSale (S)Common Stock2,933USD 323.08USD 947,581SEC filing ↗
2026-03-04Garg PushkalSale (S)Common Stock2,309USD 323.08USD 745,984SEC filing ↗
2026-03-04Fitzgerald Kevin JosephSale (S)Common Stock633USD 323.08USD 204,508SEC filing ↗
2026-03-03Garg PushkalSale (S)Common Stock1,775USD 319.74USD 567,546SEC filing ↗
2026-03-03Fitzgerald Kevin JosephSale (S)Common Stock1,652USD 319.73USD 528,189SEC filing ↗
2026-03-02Tanguler TolgaSale (S)Common Stock1,598USD 327.65USD 523,584SEC filing ↗
2026-03-02Tanguler TolgaAward / grant (A)Common Stock4,769USD 0.00USD 0SEC filing ↗
2026-03-02SUPRAN BRYANAward / grant (A)Common Stock1,539USD 0.00USD 0SEC filing ↗
2026-03-02Poulton Jeffrey V.Sale (S)Common Stock2,206USD 327.65USD 722,801SEC filing ↗
2026-03-02Poulton Jeffrey V.Award / grant (A)Common Stock4,769USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerALNY
CIK0001178670
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history1,327 transaction lines from 2020-01-03 to 2026-10-02
2 P purchase lines · 997 S sale lines · 328 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.